NNNN · Anbio Biotechnology
$9.90
-0.29% last session
End-of-day data · updated 2026-07-28
Market cap
$0B
Enterprise value
$0B
Trailing P/E
67.9
Forward P/E
—
Dividend yield
—
Beta
—
Avg volume
0M
Employees
0K
2D change
—
5D change
4.52%
10D change
7.27%
30D change
-29.94%
60D change
-70.42%
MTD change
-17.54%
YTD change
-66.15%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Signal Summary as of 2026-07-28
- RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 45.0% below the 50-day MA ($18.44).
- Price vs 200-day MA: Trading 58.9% below the 200-day MA ($24.68).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.49) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($9.12) and high ($52.10).
NNNN Price Chart
Loading chart for NNNN…
Fundamentals
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.